TScan Therapeutics (TCRX) EBITDA Margin (QoQ) (2020 - 2026)
TScan Therapeutics (TCRX) EBITDA Margin (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - |
| 10 | TScan Therapeutics | 101.01 Mn | 101.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,598.00 |
| Mar 31, 2026 | -203,790.00 |
| Dec 31, 2025 | 54,618.00 |
| Sep 30, 2025 | -21,899.00 |
| Jun 30, 2025 | 41,314.00 |
| Mar 31, 2025 | 385,086.00 |
| Dec 31, 2024 | -241,078.00 |
| Sep 30, 2024 | 325,473.00 |
| Jun 30, 2024 | -82,162.00 |
| Mar 31, 2024 | -524,676.00 |
| Dec 31, 2023 | 34,051.00 |
| Sep 30, 2023 | 14,508.00 |
| Jun 30, 2023 | -38,965.00 |
| Mar 31, 2023 | 21,043.00 |
| Dec 31, 2022 | -10,960.00 |
| Sep 30, 2022 | -11,707.00 |
| Jun 30, 2022 | 15,913.00 |
| Mar 31, 2022 | -3,740.00 |
| Dec 31, 2021 | 15,918.00 |
| Sep 30, 2021 | -28,183.00 |